Clinical trial
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria…
NCT03847909 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT03847909 |
|---|---|
| Title | A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 |
| Official title | A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria |
| Acronym | PHYOX2 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease |
| Intervention type | Drug |
| Interventions | DCR-PHXC, Sterile Normal Saline (0.9% NaCl) |
| Enrollment | 35 |
| Start date | Oct 28, 2019 |
| Primary completion | Jun 21, 2021 |
| Completion | Jun 29, 2021 |
| First posted | Feb 20, 2019 |
| Last update posted | May 22, 2024 |
| Countries | Australia, Canada, France, Germany, Israel, Italy, Japan, Lebanon, Netherlands, New Zealand, Poland, Romania and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: